POCIHIGH SIGNALRISK10-K

POCI underwent a significant strategic pivot from medical devices to defense/aerospace while simultaneously experiencing severe operational deterioration with operating losses doubling and gross profit declining 41%.

The complete removal of references to the Lighthouse Imaging acquisition and pivot toward defense/aerospace markets suggests either a failed integration or major strategic repositioning that investors were not adequately prepared for. The simultaneous doubling of operating losses while repositioning into defense markets creates execution risk and uncertainty about management's ability to successfully navigate this transition.

Comparing 2025-09-29 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

Despite a positive 338% increase in cash reserves to $1.8M and 22% growth in stockholders' equity, POCI's operational performance severely deteriorated with operating losses doubling from -$2.7M to -$5.6M and gross profit declining 41% to $3.4M. The company grew current assets by 41% and inventory by 24%, but this growth was overshadowed by the dramatic decline in profitability and worsening operating cash flow of -$3.5M, signaling significant operational challenges during what appears to be a major strategic transition.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+337.7%
$405K$1.8M

Cash position surged 337.7% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-103.8%
-$2.7M-$5.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-95.8%
-$3.0M-$5.8M

Net income declined 95.8% — review whether driven by operations, interest costs, or non-recurring items.

Gross Profit
P&L
-41.3%
$5.8M$3.4M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Assets
Balance Sheet
+41.3%
$7.1M$10.1M

Current assets grew 41.3% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-32.2%
-$2.7M-$3.5M

Operating cash flow fell 32.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+25.4%
$4.9M$6.2M

Current liabilities rose 25.4% — increased short-term obligations, watch current ratio.

Inventory
Balance Sheet
+24.2%
$2.9M$3.6M

Inventory built 24.2% — monitor whether demand supports this build or if write-downs may follow.

Accounts Receivable
Balance Sheet
+22.3%
$3.5M$4.3M

Receivables grew 22.3% — monitor days sales outstanding for collection efficiency.

Stockholders Equity
Balance Sheet
+21.8%
$10.1M$12.3M

Equity base grew 21.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2025-09-29
PRIOR — 2024-09-30
ADDED
Overview We have been a developer and manufacturer of advanced optical instruments since 1982, and we operate primarily in two key market segments: medical devices and advanced defense/aerospace products.
Within our proprietary optical and imaging technology, our unique custom designs, expert manufacturing capabilities, and advanced engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using CMOS sensor technology, some designed and manufactured for single-use, as well as other, more advanced, custom imaging and illumination products for our customers use in minimally invasive surgical procedures.
We also apply our unique technologies to applications in the Defense / Aerospace markets including applications supporting satellite network communications.
To support these two critical market categories, our business operations are conducted in four areas: systems manufacturing, engineering and product development, Ross Optical components and assemblies, and our micro-optics laboratory.
Our systems manufacturing operations assemble and manufacture components and systems for both medical device and advanced aerospace customers who choose to outsource these services based on our ability to handle high complexity components, specific optical technologies, micro-optical assemblies and other advanced manufacturing challenges.
+7 more — sign up free →
REMOVED
Overview We have been a developer and manufacturer of advanced optical instruments since 1982.
Our proprietary medical instrumentation line, unique custom design and manufacturing capabilities, and expert engineering and development has generated traditional proprietary endoscopes and endocouplers as well as other custom imaging and illumination products for our customers use in minimally invasive surgical procedures.
Effective October 1, 2021, we acquired the operating assets of Lighthouse Imaging, LLC of Windham, Maine.
Our Lighthouse Imaging division supplements our operations as a manufacturer of advanced optical imaging systems and accessories and has provided further expertise in electrical engineering and development of end-to-end medical visualization devices.
Product development competencies at Lighthouse Imaging include Systems, Optical, Mechanical, Electrical and Process Development Engineering.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →